Researchers create new path to target hard-to-drug prostate cancer protein
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 10:16 ET (30-Oct-2026 14:16 GMT/UTC)
In the largest genetic study of irritable bowel syndrome (IBS) to date, researchers analysed DNA and health-related data from nearly 2.8 million people.
The results point to new biological mechanisms connecting IBS with lipid metabolism and broader cardiometabolic health.
(Boston)—Afzalbek Fayzullaev, a second-year student at Boston University Chobanian & Avedisian School of Medicine, has been awarded the prestigious ASTRO (American Society for Radiation Oncology) Medical Student Fellowship Award for his project, “Readability of Patient Education Materials for Radiation Oncology and Treatment Adherence at an Urban Safety Net Hospital.”
Boston University Chobanian & Avedisian School of Medicine’s longest NIH-funded research training program, “Biology of the Lung: A Multi-Disciplinary Program,” has received an additional five-year, T32 award to continue providing multidisciplinary training and exposure to collaborative lung biology in three scientific areas that are special strengths at Boston University: development and regenerative medicine; immunology and infection; and biomedical data sciences.
Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy for chronic ischemic stroke were presented today at the ISSCR 2026 Annual Meeting.
The data include extended follow-up from Phase I studies evaluating hNPC01, an iPSC-derived forebrain neural progenitor cell therapy designed to promote repair of stroke-damaged brain tissue. The findings provide new insight into the long-term safety, feasibility, and biological activity of this regenerative approach in patients living with chronic motor disability following stroke.
The International Society for Stem Cell Research (ISSCR) today announced the presentation of new clinical data from the STEM-PD Phase I/II clinical trial at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the treatment of Parkinson's disease.
The findings provide new insights into the safety, feasibility, and biological activity of stem cell-derived dopaminergic cell transplantation in patients with Parkinson’s disease and represent another important step in the clinical translation of regenerative medicine for neurodegenerative disease.